Outcomes of Nivolumab and Ipilimumab in Kidney Cancer
Author Information
Author(s): Taniguchi Tomoki, Iinuma Koji, Kawada Kei, Ishida Takashi, Takagi Kimiaki, Tomioka Masayuki, Kawase Makoto, Kawase Kota, Nakane Keita, Tobisawa Yuki, Koie Takuya
Primary Institution: Gifu University
Hypothesis
What are the real-world oncological outcomes of nivolumab plus ipilimumab in patients with advanced or metastatic renal cell carcinoma?
Conclusion
The study found that the oncological outcomes of nivolumab plus ipilimumab treatment in Japanese patients with metastatic renal cell carcinoma were comparable to those in previous clinical trials.
Supporting Evidence
- The median progression-free survival was 13.3 months.
- The objective response rate was 47.6%.
- The disease control rate was 78.6%.
- The median overall survival was 50.9 months.
- Patients with intermediate-risk RCC had a median overall survival that was not reached.
Takeaway
This study looked at how well a combination of two cancer drugs works for patients with kidney cancer in Japan, and it found that the results are similar to those seen in other studies.
Methodology
This was a multicenter, retrospective cohort study reviewing clinical records of patients treated with nivolumab plus ipilimumab at nine centers in Japan.
Potential Biases
Potential selection bias due to treatment decisions based on institutional criteria.
Limitations
The study was retrospective, had a small sample size, and a relatively short follow-up period.
Participant Demographics
The median age of participants was 68 years, with 71.4% diagnosed with clear cell renal cell carcinoma.
Statistical Information
P-Value
p = 0.028
Confidence Interval
95% CI, 1.5–13.3
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website